Introduction {#s1}
============

The *ARID1A* gene encoding AT-Rich Interactive Domain-containing protein 1A is known as a member of the switching/sucrose non-fermentable (SWI/SNF) complex involved in chromatin remodeling.[@R1] Mutations in and loss of the *ARID1A* gene mostly lead to its inactivation and ARID1A protein loss.[@R2] Certain types of cancer, including clear cell ovarian carcinoma (46%--50%), gastric adenocarcinoma (10%--35%), and cholangiocarcinoma (15%--27%), frequently harbor *ARID1A* alterations.[@R2] To date, clinical and preclinical data indicate that *ARID1A* alterations may sensitize tumors to drugs targeting the ataxia telangiectasia and Rad3-related (ATR) protein, the enhancer of zeste 2 (EZH2), or the phosphatidylinositol-3-kinase (PI3K) pathway,[@R5] but no therapies targeting *ARID1A* alterations have been approved. Importantly, Shen *et al* demonstrated that *ARID1A* alterations interact with the mismatch repair (MMR) protein MSH2 and, hence, compromise MMR.[@R3] Tumors formed by an *ARID1A*-deficient ovarian cancer cell line in syngeneic mice exhibited higher mutation load, as well as increased numbers of tumor-infiltrating lymphocytes and elevated programmed cell death-ligand 1 (PD-L1) expression. Furthermore, administration of anti-PD-L1 antibody decreased cancer burden and extended survival of mice bearing *ARID1A*-deficient but not *ARID1A* wild-type ovarian tumors.[@R3] Interestingly, alterations in the polybromo-1 (*PBRM1*) gene, which is another member of the SWI/SNF complex, have been reported to correlate with salutary effects in cancer patients receiving checkpoint blockade inhibitors, though the clinical evidence remains controversial.[@R11] In gastric cancers, *ARID1A* alterations are associated with Epstein-Barr virus infection, which is in turn associated with checkpoint blockade response.[@R13] Herein, for the first time to our knowledge, we investigated the clinical correlation between *ARID1A* alterations and treatment benefit after anti-programmed cell death-1 (PD-1)/PD-L1 immunotherapy in the human pan-cancer setting.

Materials and methods {#s2}
=====================

Study population and next-generation sequence {#s2-1}
---------------------------------------------

In a cohort of 3403 eligible patients at the Center for Personalized Cancer Therapy (University of California San Diego Moores Cancer Center), whose tissue DNA was analyzed by next-generation sequencing (NGS) by Foundation Medicine, Inc. (CLIA-licensed and CAP-accredited laboratory. Cambridge, Massachusetts, USA <https://www.foundationmedicine.com>), we reviewed the clinicopathological and genomic information of patients whose tumors were pathologically diagnosed as one of nine types of cancer that frequently harbored *ARID1A* alterations (\>5% of prevalence in this cohort): non-small cell lung cancer, colorectal adenocarcinoma, breast cancer, melanoma, pancreatic ductal adenocarcinoma, cholangiocarcinoma/hepatocellular carcinoma, gastric/esophageal adenocarcinoma, uterine/ovary endometrial (endometrioid) carcinoma (including clear-cell carcinoma), and urothelial bladder carcinoma. Tissue DNA sequencing at the laboratory was approved by the US Food and Drug Administration in November 2017 and designed to include all genes somatically altered in human solid malignancies that were validated as targets for therapy, either approved or in clinical trials, and/or that were unambiguous drivers of oncogenesis based on available knowledge.[@R14] Although the gene panel expanded with time (236--324 genes), the interrogation of the *ARID1A* gene was considered consistent. Only characterized *ARID1A* alterations were considered in this study (variants of unknown significant were excluded). In terms of microsatellite instability (MSI) status, 114 intron homo-polymer repeat loci with adequate coverage are analyzed for length variability and compiled into an overall score via principal components analysis.[@R16] Measuring genes interrogated on the tissue DNA NGS and extrapolating to the genome as a whole as previously validated determined tumor mutational burden (TMB).[@R18] TMB was classified to three categories: high (≥20 mutations/mb), intermediate (6--19 mutations/mb), and low (\<6 mutations/mb).

Statistics {#s2-2}
----------

Using the Mann-Whitney U test and Fisher's exact test, respectively, we compared categorical and continuous data. Progression-free survival (PFS) and overall survival (OS) data were measured from date of the initiation of anti-PD-1/PD-L1 immunotherapy and plotted by the Kaplan-Meier method. Data were censored if patient was progression free or alive (for PFS and OS, respectively) at last follow-up. The curves were compared by using the log-rank test. In multivariate analysis to investigate independent predictive factors for the PFS after anti-PD-1/PD-L1 immunotherapy, we used Cox's proportional hazard model for estimating HR and its 95% CI (variables with p\<0.1 in the univariate analyses were entered into the multivariate analysis). RO performed and verified statistical analysis using SPSS V.24 software.

Results and discussion {#s3}
======================

Starting with 3403 eligible patients who underwent tissue DNA NGS, we found 1540 patients with nine types of cancer diagnoses that had \>5% prevalence of characterized *ARID1A* alterations in tissue DNA NGS ([figure 1A](#F1){ref-type="fig"} and [online supplementary figure 1](#SP1){ref-type="supplementary-material"}). Of 161 patients with ≥1 characterized *ARID1A* alteration in diverse types of cancer, 142 had *ARID1A* substitution or frameshift alterations, while the remaining 19 had insertions, deletions, allelic loss, rearrangement, or truncation. Endometrial and gastroesophageal cancers were the tumor types in which *ARID1A* alterations were most frequent---49% and 20% of cases, respectively ([figure 1A](#F1){ref-type="fig"}). The median number of genomic coalterations among tumors with *ARID1A* alterations was 6 (range, 1--72) (not including *ARID1A* alterations), which was significantly higher than the median of 4 alterations (range, 0--61) among those cancers with wild-type *ARID1A* (p\<0.001). The rate of MSI-high was significantly higher in tumors with *ARID1A* alterations than in those with wild-type *ARID1A* (20% vs 0.9%; p\<0.001) and in multiple individual tumor types as well (eg, MSI-high in *ARID1A*-altered vs wild-type endometrial cancer, 41% vs 0%, p=0.001) ([figure 1B](#F1){ref-type="fig"}). Similarly, TMB-high (≥20 mutations/mb) was more often observed in tumors with *ARID1A* alterations than in those with wild-type *ARID1A* (26% vs 8.4%; p\<0.001) and in individual tumor types (eg, endometrial cancer, 35% vs 0%, p=0.001) ([figure 1C](#F1){ref-type="fig"}).
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![(A) Prevalence of characterized *ARID1A* alterations in tissue DNA NGS according to cancer types (n=1540). (B) Frequency of MSI-high according to *ARID1A* status (microsatellite status was available in 1093 patients (71.0%)). (C) Frequency of TMB-high according to *ARID1A* status (TMB-status was available in 1411 patients (91.6%); p values are for TMB-high rates): TMB-high (≥20 mutations/mb); TMB-intermediate (6--19 mutations/mb); TMB-low (\<6 mutations/mb). *ARID1A*, AT-Rich Interactive Domain-containingprotein 1A; bladder, urothelial bladder carcinoma; breast, breast cancer; cholangio/HCC, cholangiocarcinoma and hepatocellular carcinoma; colorectal, colorectal adenocarcinoma; endometrial, uterine/ovary endometrial (endometrioid) carcinoma; gastroesophageal, gastric/esophageal adenocarcinoma; MSI, microsatellite instability; NGS, next-generation sequencing; NSCLC, non-small cell lung cancer; pancreatic, pancreatic ductal adenocarcinoma; TMB, tumor mutational burden.](jitc-2019-000438f01){#F1}

Overall, 375 patients (24%) among the 1540 patients with the nine types of cancer with \>5% *ARID1A* alterations received anti-PD-1/PD-L1 immunotherapy in the advanced/metastatic disease setting (see [online supplementary figure 1](#SP1){ref-type="supplementary-material"}). MSI-high and TMB-high were seen in 4.3% (n=16) and 17% (n=65) of these 375 patients, respectively. As shown in [figure 2A](#F2){ref-type="fig"}, patients with *ARID1A*-altered tumors showed a significantly longer PFS than those with the wild-type tumors (10.9 months vs 3.9 months, p=0.006) from the start of anti-PD-1/PD-L1 immunotherapy. When PFS was analyzed according to cancer diagnosis (only tumor types with ≥5 patients with *ARID1A* alterations), similar sensitivity was observed in individual tumor types (eg, colorectal cancer (5.2 months vs 2.1 months, p=0.005); endometrial cancer (4.6 months vs 3.0 months, p=0.02)) (see [online supplementary figure 2](#SP1){ref-type="supplementary-material"}). Importantly, even when only patients without MSI-high were included to the analysis, *ARID1A*-altered tumors showed a significantly longer PFS than those with wild-type tumors: HR (95% CI), 0.62 (0.40 to 0.97); p=0.03 ([figure 2B](#F2){ref-type="fig"}). In the same way, when only patients without TMB-high were included to the analysis, patients with *ARID1A*-altered tumors (vs *ARID1A* wild-type) showed a trend towards longer PFS: HR (95% CI), 0.69 (0.43 to 1.08) although not statistically significant (p=0.10) (see [online supplementary figure 3](#SP1){ref-type="supplementary-material"}) (small numbers of patients precluded analysis of patients with MSI-high or TMB-high who had *ARID1A* alterations vs not). When examining OS in *ARID1A*-altered versus the wild-type patients, median OS time was longer in the *ARID1A*-altered group (30.8 months vs 20 months), but this did not reach statistical significance (p=0.13) (see [online supplementary figure 4](#SP1){ref-type="supplementary-material"}). In order to better determine if the correlation between *ARID1A* alterations and longer PFS was independent of specific confounding variables, we performed a multivariate analysis (patient characteristics of *ARID1A*-altered vs wild-type patients are shown in [table 1](#T1){ref-type="table"}). Our Cox-regression model demonstrated that *ARID1A* alterations were selected as an independent predictor of better outcome (PFS) after anti-PD-1/PD-L1 immunotherapy (HR (95% CI), 0.61 (0.40 to 0.94); p=0.03) ([table 2](#T2){ref-type="table"}).

![Kaplan-Meier curve of PFS according to *ARID1A* status. (A) Among patients who received anti-programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) immunotherapy (n=375). (B) Among patients without microsatellite instability-high who received anti-PD-1/PD-L1 immunotherapy (n=359). Similar results were seen even if the MS-unknown (n=60) were excluded (p=0.02). *ARID1A*, AT-Rich Interactive Domain-containingprotein 1A; MS, microsatellite status; PFS, progression-free survival.](jitc-2019-000438f02){#F2}

###### 

Characteristics of patients who underwent anti-PD-1/PD-L1 immunotherapy (n=375)

  ------------------------------------------------------------------------------------------------------------------------------
  Variables                                                             *ARID1A*-altered\   *ARID1A*-wild type\   P value
                                                                        (n=46)              (n=329)               
  --------------------------------------------------------------------- ------------------- --------------------- --------------
  **Basic characteristics and tissue DNA next-generation sequencing**                                             

  Age at tissue DNA analysis, years                                                                               

   Median (range)                                                       65.1 (34.0--89.4)   63.0 (22.3--93.7)      0.49

  Gender                                                                                                           

   Female                                                               25 (54.3%)          142 (43.2%)            0.16

   Male                                                                 21 (45.7%)          187 (56.8%)            --

  Diagnosis                                                                                                        

   Lung cancer, non-small cell                                          7 (15.2%)           104 (31.6%)            **0.02**

   Colorectal adenocarcinoma                                            12 (26.1%)          37 (11.2%)             **0.009**

   Breast cancer                                                        1 (2.2%)            24 (7.3%)              0.34

   Melanoma                                                             6 (13.0%)           91 (27.7%)             **0.046**

   Pancreatic ductal adenocarcinoma                                     1 (2.2%)            7 (2.1%)               \>0.99

   Cholangiocarcinoma/hepatocellular carcinoma                          2 (4.3%)            13 (4.0%)              0.71

   Gastric/esophageal adenocarcinoma                                    5 (10.9%)           16 (4.9%)              0.16

   Endometrial carcinoma                                                10 (21.7%)          13 (4.0%)              \<**0.001**

   Urothelial bladder carcinoma                                         2 (4.3%)            24 (7.3%)              0.76

  Characterized alterations                                                                                       

   Median (range)                                                       8 (2--57)\*         5 (1--24)              \<**0.001**

  Microsatellite status                                                                                            

   MSI-high                                                             13 (28.3%)          3 (0.9%)               \<**0.001**

   Stable                                                               31 (67.4%)          268 (81.5%)            **0.03**

   Unknown                                                              2 (4.3%)            58 (17.6%)             **0.02**

  Tumor mutational burden, mutations/mb                                                                            

   Median (range)†                                                      16.0 (1.0--321.0)   6.1 (0.0--222.0)       \<**0.001**

   ≥20 (high)                                                           18 (39.1%)          47 (14.3%)             \<**0.001**

   6--19 (intermediate)                                                 16 (34.8%)          129 (39.2%)            0.63

   \<6 (low)                                                            8 (17.4%)           133 (40.4%)            **0.002**

   Unknown                                                              4 (8.7%)            20 (6.1%)              0.52

  **Anti-PD-1/PD-L1 immunotherapy**                                                                               

  Administered as                                                                                                  

   1st line                                                             8 (17.4%)           113 (34.3%)            **0.03**

   ≥2nd line                                                            38 (82.6%)          216 (65.7%)            --

  Regimen of anti-PD-1/PD-L1 immunotherapy                                                                         

   Anti-PD-1/PD-L1 monotherapy                                          25 (54.3%)          170 (51.7%)            0.76

   With molecular targeting drug                                        7 (15.2%)           36 (10.9%)             0.46

   With CTLA4 inhibitor                                                 6 (13.0%)           56 (17.0%)             0.67

   With cytotoxic chemotherapy                                          4 (8.7%)            33 (10.0%)             \>0.99

   With molecular targeting and cytotoxic drugs                         2 (4.3%)            2 (0.6%)               0.08

   Others‡                                                              2 (4.3%)            32 (9.7%)              0.41
  ------------------------------------------------------------------------------------------------------------------------------

All p-values \<0.05 are listed in bold.

\*Excluded *ARID1A* alterations.

†Among 1411 patients whose TMB data were available.

‡With NKG2A inhibitor (n=9); with CD73 inhibitor (n=8); with IDO1 inhibitor (n=6); with CD122-preferential IL-2 pathway agonist (n=5); with CTLA4 inhibitor and molecular targeting drug (n=2); with OX40 agonist (n=2); with CEA/BiTE inhibitor (n=1); with 4-1BB inhibitor (n=1).

*ARID1A*, AT-Rich Interactive Domain-containing protein 1A gene; bladder, urothelial bladder carcinoma; breast, breast cancer; cholangio/HCC, cholangiocarcinoma and hepatocellular carcinoma; colorectal, colorectal adenocarcinoma; CTLA4, cytotoxic T lymphocyte antigen 4; endometrial, uterine/ovary endometrial (endometrioid) carcinoma; gastroesophageal, gastric/esophageal adenocarcinoma; MSI, microsatellite instability; NSCLC, non-small cell lung cancer; pancreatic, pancreatic ductal adenocarcinoma; PD-1/PD-L1, programmed cell death-1 and its ligand.

###### 

Univariate and multivariate analyses for progression-free survival after anti-PD-1/PD-L1 immunotherapy (n=375). Variables with p\<0.10 in the univariate analyses were entered into the multivariate analysis

  Characteristics                                          Progression-free survival                                        
  -------------------------------------------------------- --------------------------- ------------- ---------------------- -------------
  Age, years\*                                                                                                              
   ≥63 (n=195) vs \<63 (n=180)                             4.6 vs 4.0                  0.57          --                     --
  Gender                                                                                                                    
   Female (n=167) vs male (n=208)                          3.8 vs 5.1                  0.08          1.16 (0.91 to 1.47)    0.23
  Diagnosis                                                                                                                 
   NSCLC (n=111) vs not (n=264)                            4.9 vs 4.1                  0.99          --                     --
   Colorectal (n=49) vs not (n=326)                        2.9 vs 4.6                  **0.02**      1.38 (0.98 to 1.97)    0.07
   Melanoma (n=97) vs not (n=278)                          7.8 vs 3.7                  \<**0.001**   0.69 (0.50 to 0.95)    **0.02**
   Endometrial (n=23) vs not (n=352)                       3.7 vs 4.2                  0.64          --                     --
  Number of characterized alteration in tissue DNA†                                                                         
   ≥6 (n=195) vs \<6 (n=180)                               4.2 vs 4.2                  **0.03**      1.09 (0.84 to 1.41)    0.51
  MSI-status                                                                                                                
   MSI-high (n=16) vs not‡ (n=359)                         12.3 vs 4.0                 **0.01**      0.74 (0.33 to 1.64)    0.46
  TMB, mutations/mb                                                                                                         
   TMB-high (≥20) (n=65) vs not‡ (n=310)                   13.6 vs 3.7                 \<**0.001**   0.47 (0.31 to 0.71)    \<**0.001**
  ARID1A status                                                                                                             
   *ARID1A*-altered (n=46) vs wild type (n=329)            10.9 vs 3.9                 **0.006**     0.61 (0.39 to 0.94)§   **0.02**
  Regimen of anti-PD-1/PD-L1 immunotherapy                                                                                  
   Administered as 1st line (n=121) vs ≥2nd line (n=254)   7.4 vs 3.7                  **0.001**     0.80 (0.60 to 1.07)    0.13

All p-values \<0.05 are listed in bold.

\*Age at tissue DNA analysis. Dichotomized by the median.

†Dichotomized by the median.

‡Including patients whose data were not reported.

§The HR (95% CI) was similar (0.55 (0.34 to 0.88), p=0.01) even if patients with MS-unknown or TMB-unknown (n=70) were excluded.

*ARID1A*, AT-Rich Interactive Domain-containing protein 1A gene; CI, confidence interval; HR, hazard ratio; MSI, microsatellite instability; NSCLC, non-small cell lung cancer; PD-1/PD-L1, programmed cell death-1 and its ligand; TMB, tumor mutational burden.

In conclusion, 28% of *ARID1A*-altered tumors (n=32 of 114 patients whose microsatellite and TMB status were both available) had either MSI-high or TMB-high (or both), and the rate of MSI-high and TMB-high was significantly higher in *ARID1A*-altered versus wild-type tumors. These findings are consistent with previous reports that *ARID1A* deficiency is correlated with MMR deficiency.[@R3] *ARID1A* alterations were independently and significantly associated with longer PFS after anti-PD-1/PD-L1 immunotherapy (regardless of microsatellite and TMB status). This study has several limitations such as the small number of patients with each cancer type, which restricted our ability to analyze individual tumor histologies. Nevertheless, the results suggest generalizability across tumor types. Another limitation was that improvement in OS in *ARID1A*-altered patients (vs wild-type) did not reach statistical significance; larger numbers of patients are needed to validate this endpoint. Therefore, *ARID1A* alterations may be a genomic marker of checkpoint blockade sensitivity, in addition to other putative markers such as MSI-high and TMB-high.[@R20] Our observations indicate that *ARID1A* alterations warrant further studies with longer follow-up and larger numbers of patients in order to confirm if they can be added to the armamentarium of genomic markers that are exploitable for matching patients to immunotherapy in the pan-cancer setting.[@R23]
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